Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01059643 · ClinicalTrials.gov registry record · Phase 2
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
NCT01059643 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 103 participants.
The verdict
NCT01059643, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
Study Summary
The purpose of the study is to estimate the rate of response for patients with ovarian, non-small cell lung, prostate, colorectal, gastroesophageal, and head and neck cancers who are administered LY2523355.
Interventions
- DRUG pegfilgrastim
- DRUG LY2523355
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01059643
The ClinicalTrials.gov registry entry for NCT01059643 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pegfilgrastim is the first listed.
NCT01059643 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01059643 about?
NCT01059643 is a clinical study titled "A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck". The purpose of the study is to estimate the rate of response for patients with ovarian, non-small cell lung, prostate, colorectal, gastroesophageal, and head and neck cancers who are administered LY2523355.
What is the current status of trial NCT01059643?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2011-04. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01059643?
The interventions under investigation include: pegfilgrastim (DRUG), LY2523355 (DRUG).
Who is sponsoring clinical trial NCT01059643?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.